NASDAQ:DOXAmdocs Stock Price, Forecast & News

Amdocs' stock was trading at $61.42 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, DOX shares have increased by 0.8% and is now trading at $61.91.
View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amdocs in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Amdocs.

Amdocs is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020.
View our earnings forecast for Amdocs.

Amdocs Limited (NASDAQ:DOX) released its earnings results on Thursday, May, 7th. The technology company reported $1.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.06 by $0.02. The technology company had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.04 billion. Amdocs had a return on equity of 16.03% and a net margin of 11.98%. The business's quarterly revenue was up 2.8% compared to the same quarter last year. During the same quarter last year, the business earned $1.06 EPS.
View Amdocs' earnings history.

Amdocs declared a quarterly dividend on Thursday, May 7th. Shareholders of record on Tuesday, June 30th will be given a dividend of $0.327 per share on Friday, July 24th. This represents a $1.31 dividend on an annualized basis and a yield of 2.11%. The ex-dividend date of this dividend is Monday, June 29th.
View Amdocs' dividend history.

Amdocs updated its fourth quarter earnings guidance on Wednesday, August, 5th. The company provided earnings per share (EPS) guidance of $1.16-1.22 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.16. The company issued revenue guidance of $1.015-1.055 billion, compared to the consensus revenue estimate of $1.03 billion.

5 brokerages have issued 12 month price objectives for Amdocs' shares. Their forecasts range from $72.00 to $85.00. On average, they anticipate Amdocs' stock price to reach $76.40 in the next twelve months. This suggests a possible upside of 23.4% from the stock's current price.
View analysts' price targets for Amdocs.

Media stories about DOX stock have trended neutral on Wednesday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Amdocs earned a coverage optimism score of 0.2 on InfoTrie's scale. They also assigned media stories about the technology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term.
View the latest news about Amdocs.

Amdocs saw a decrease in short interest during the month of July. As of July 15th, there was short interest totaling 2,590,000 shares, a decrease of 9.1% from the June 30th total of 2,850,000 shares. Based on an average daily trading volume, of 890,300 shares, the short-interest ratio is presently 2.9 days. Approximately 1.9% of the shares of the stock are short sold.
View Amdocs' Current Options Chain.

Some companies that are related to Amdocs include Accenture (ACN), IBM (IBM), Cognizant Technology Solutions (CTSH), EPAM Systems (EPAM), Leidos (LDOS), Gartner (IT), Booz Allen Hamilton (BAH), Caci International (CACI), Mantech International (MANT), Teradata (TDC), Virtusa (VRTU), Unisys (UIS), Forrester Research (FORR), The Hackett Group (HCKT) and Servicesource International (SREV).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amdocs investors own include AbbVie (ABBV), Comcast (CMCSA), AT&T (T), Walt Disney (DIS), Gilead Sciences (GILD), Home Depot (HD), Intel (INTC), Pfizer (PFE), Verizon Communications (VZ) and Cisco Systems (CSCO).

Amdocs trades on the NASDAQ under the ticker symbol "DOX."

Amdocs' stock is owned by many different institutional and retail investors. Top institutional shareholders include LSV Asset Management (3.80%), Robeco Institutional Asset Management B.V. (1.32%), Principal Financial Group Inc. (0.90%), First Trust Advisors LP (0.82%), Wedge Capital Management L L P NC (0.63%) and CWM LLC (0.41%).

DOX stock was sold by a variety of institutional investors in the last quarter, including Bessemer Group Inc., Denali Advisors LLC, Russell Investments Group Ltd., Robeco Institutional Asset Management B.V., WINTON GROUP Ltd, Raymond James & Associates, Grandfield & Dodd LLC, and Stone Ridge Asset Management LLC.

DOX stock was bought by a variety of institutional investors in the last quarter, including LSV Asset Management, Wedge Capital Management L L P NC, CWM LLC, Principal Financial Group Inc., UNIVEST FINANCIAL Corp, Exane Asset Management, Optimal Asset Management Inc., and Palouse Capital Management Inc..

Shares of DOX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of DOX stock can currently be purchased for approximately $61.91.

Amdocs has a market capitalization of $8.34 billion and generates $4.09 billion in revenue each year. The technology company earns $479.45 million in net income (profit) each year or $4.07 on an earnings per share basis. Amdocs employs 24,516 workers across the globe.

The official website for Amdocs is www.amdocs.com.

Amdocs' mailing address is 1390 Timberlake Manor Parkway, Chesterfield MO, 63017. The technology company can be reached via phone at 1 314 212 7000 or via email at [email protected]